GSK Provides an Update on CALM-1 and CALM-2 Phase III Trials for Camlipixant in Refractory Chronic Cough (RCC)

Phase 3camlipixantNeutral

AI Analysis

Summary

GSK provided an update on the CALM-1 and CALM-2 Phase III trials evaluating camlipixant, a P2X3 receptor antagonist, in adults with refractory chronic cough. The article does not disclose trial outcomes or clinical data.

Clinical Trial Data

Phase

Phase III

Importance:6/10

Sentiment:

0.00

Phase 3Clinical TrialP2X3 antagonistRespiratory

Related Companies

$GSK

Read the original article

Published by Drugs.com Clinical Trial Results on July 17, 2026 8:07 PM

Read Original